With these agreements, the respective parties will work to advance therapeutic candidates for treating fibrotic diseases, osteoarthritis, and Alzheimer’s disease.

AVOS Life Sciences has analysed the revenue contribution of each therapeutic area to the major Rx drug portfolios (MRDP; the collection of branded drugs that are each predicted to achieve at least ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Q4 2024 Management View Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in ...

Sirnaomics is poised to improve outcomes in therapeutic areas such as oncology and fibrosis with a pipeline of prospects built on proprietary delivery technology platforms able to deliver siRNAs ...